Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118440 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Naoko Hosono und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Fukui, 23-3, Matsuokashimoaizuki, Eiheiji, Fukui 910-1193, Japan. Electronic address: hosono@u-f…. Hauptthemen laut MEDLINE: Precision Medicine, Leukemia, Myeloid, Acute, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 249 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Since the discovery of cytotoxic agents in the mid-20th century, acute leukemia has consistently served as a model for oncology research. As the Human Genome Project and subsequent genomic profiling elucidated the landscape of somatic mutations and cytogenetic aberrations driving leukemogenesis, the development of molecularly targeted therapies has dramatically accelerated, yielding significant improvements in patient outcomes. In acute myeloid leukemia (AML), the emergence of selective inhibitors targeting high-frequency alterations such as FLT3, NPM1, and IDH1/2 has redefined the standard of care, demonstrating superior efficacy when combined with conventional intensive chemotherapy or hypomethylating agents. Simultaneously, for acute lymphoblastic leukemia (ALL), in addition to the significant improvements achieved by tyrosine kinase inhibitors (TKIs) for BCR-ABL-positive ALL, the advent of CD19- or CD22-targeted monoclonal antibodies and CAR-T cell therapies has marked an epoch-making milestone, representing a major paradigm shift in the management of relapsed or refractory cases. Bridging these two distinct lineages, menin inhibitors have emerged as a novel class of agents targeting a common pathogenic mechanism in KMT2A-rearranged AML/ALL and NPM1-mutated AML, exhibiting promising antileukemic activity across these subtypes. In this review, we describe the evolution of leukemia therapy-highlighting historical trajectory across AML, APL, and ALL from uniform cytotoxic chemotherapy to molecularly targeted agents, antibody-based therapies, and chemo-free paradigms, while outlining future perspectives for precision hematology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University of Fukui, 23-3, Matsuokashimoaizuki, Eiheiji, Fukui 910-1193, Japan. Electronic address: hosono@u-fukui.ac.jp.
- Department of Hematology and Oncology, University of Fukui, 23-3, Matsuokashimoaizuki, Eiheiji, Fukui 910-1193, Japan.
Zitieren
APA
Hosono, N., Ida, N., & Yamauchi, T. (2026). Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118440
Vancouver
Hosono N, Ida N, Yamauchi T. Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118440
BibTeX
@article{Hosono2026,
author = {Hosono, Naoko and Ida, Naoko and Yamauchi, Takahiro},
title = {Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118440}
}
EUVIMED